Showing 12 posts of 12 posts found.

Janssen sign

Johnson & Johnson’s arthritis drug shows promising results in Phase III trial

March 16, 2021
Manufacturing and Production Janssen, Johnson & Johnson, PSA, Tremfya, arthritis

Johnson & Johnson’s TREMFYA treatment for active Psoriatic Arthritis (PsA) has returned positive results in its Phase III trial.


European approval for Janssen’s Tremfya in active psoriatic arthritis, either alone or in combo

December 2, 2020
Research and Development, Sales and Marketing Europe, Janssen, Tremfya

The European Commission has authorised Janssen’s interleukin (IL)-23 inhibitor Tremfya (guselkumab) in the treatment of active psoriatic arthritis (PsA), either …


CHMP recommendation for Janssen’s Tremfya in active psoriatic arthritis

October 19, 2020
Sales and Marketing CHMP, EMA, Janssen, Tremfya

Janssen’s interleukin (IL)-23 inhibitor Tremfya (guselkumab) has scored a recommendation from the EMA’s Committee for Medicinal Products for Human Use …


Jannsen’s Tremfya becomes first FDA-approved IL-23 inhibitor for active psoriatic arthritis

July 15, 2020
Research and Development, Sales and Marketing FDA, Jannsen, Tremfya, active psoriatic arthritis

Janssen has reported that its therapy Tremfya (guselkumab) has become the first selective interleukin (IL)-23 inhibitor approved by the FDA …


Tremfya’s skin clearance benefit lasts up to four years in plaque psoriasis patients, Janssen says

June 15, 2020
Research and Development, Sales and Marketing Janssen, Tremfya, plaque psoriasis

Janssen has revealed new data on its interleukin (IL)-23 inhibitor Tremfya (guselkumab) at the American Academy of Dermatology (AAD) virtual …


Janssen’s Tremfya shows skin clearance benefit for psoriatic arthritis patients in two Phase 3 studies

June 4, 2020
Research and Development Janssen, Tremfya, psoriatic arthritis

Janssen has revealed data from two Phase 3 trials for Tremfya (guselkumab), showing improvement in skin clearance and symptoms in …


Lilly’s Taltz beats Janssen’s Tremfya at Phase 4 in plaque psoriasis

August 15, 2019
Research and Development Eli Lilly, Taltz, Tremfya, pharma, psoriasis

Eli Lilly has unveiled new Phase 4 data supporting the efficacy and safety of Taltz (ixekizumab) when compared to Janssen’s …


Janssen’s Tremfya maintains skin clearance after 3 years in plaque psoriasis

October 22, 2018
Research and Development, Sales and Marketing Janssen, Tremfya, pharma, plaque psoriasis, psoriasis

Janssen has revealed new long-term data for its IL-23 inhibitor Tremfya (guselkumab) in moderate to severe plaque psoriasis, demonstrating skin …


Phase 3 data presents strong case for switching from Humira to Janssen’s Tremfya in plaque psoriasis

September 13, 2018
Research and Development Humira, Janssen, Tremfya, pharma, psoriasis

Janssen has unveiled new Phase 3 data derived from two separate trials on the efficacy and benefits of switching to …

Janssen’s Tremfya gets go-ahead from NICE in plaque psoriasis

May 11, 2018
Medical Communications, Sales and Marketing Janssen, NICE, Tremfya, UK, pharma, psoriasis

NICE, the UK’s drug watchdog for the NHS, has decided that Janssen’s Tremfya (guselkumab) should be used routinely through the …

J&J uses FDA Priority Review Voucher to snag psoriasis approval

July 14, 2017
Medical Communications, Sales and Marketing Janssen, Johnson & Johnson, Tremfya, biotech, drugs, pharma, pharmaceutical

The FDA has handed out another approval, as the agency now easily surpasses last year’s figure of 22 already, this …

Latest content